| Literature DB >> 23195962 |
Grace C Lee, Hansheng Liou, Russell Yee, Clifford F Quan, Katherine Neldner.
Abstract
Studies evaluating the outcomes of an extended-infusion (EI) piperacillin-tazobactam dosing strategy in specific cohorts of critically ill patients are lacking. A retrospective, pre-implementation and post-implementation study of 148 critically ill patients was conducted to compare EI and traditional infusion piperacillin-tazobactam. In this retrospective study, the EI piperacillin-tazobactam dosing strategy was associated with improved 30-day mortality. EI piperacillin-tazobactam may be an effective alternative to TI of piperacillin-tazobactam among critically ill patients treated for suspected gram-negative infections.Entities:
Mesh：
Substances：
Year: 2012 PMID： 23195962 DOI： 10.1016/j.clinthera.2012.11.005
Source DB: PubMed Journal: Clin Ther ISSN： 0149-2918 Impact factor: 3.393